Entity usage

Showing below up to 50 results in range #51 to #100.

51. Dynamic undirected graphical models for time-varying clinical symptom and neuroimaging networks: Label: en
52. Prefiltered component-based greedy (PreCoG) scan method: Label: en
53. Determining sample size in a personalized randomized controlled (PRACTical) trial: Label: en
54. Exploiting relationship directionality to enhance statistical modeling of peer-influence across social networks: Label: en
55. A sequential, multiple assignment, randomized trial design with a tailoring function: Label: en
56. A Bayesian semi-parametric scalar-on-function regression with measurement error using instrumental variables: Label: en
57. Covariate-adjusted generalized pairwise comparisons in small samples: Label: en
58. BHAFT: Bayesian heredity-constrained accelerated failure time models for detecting gene-environment interactions in survival analysis: Label: en
59. The objective function controversy for group testing: much ado about nothing?: Label: en
60. Using longitudinal targeted maximum likelihood estimation in complex settings with dynamic interventions: Label: en
61. A spatially discrete approximation to log-Gaussian Cox processes for modelling aggregated disease count data: Label: en
62. Frailty proportional mean residual life regression for clustered survival data: a hierarchical quasi-likelihood method: Label: en
63. A general approach to detect gene (G)-environment (E) additive interaction leveraging G-E independence in case-control studies: Label: en
64. Mediation analysis of time-to-event endpoints accounting for repeatedly measured mediators subject to time-varying confounding: Label: en
65. Sample size calculation for the Andersen-Gill model comparing rates of recurrent events: Label: en
66. Dynamic prediction of Alzheimer's disease progression using features of multiple longitudinal outcomes and time-to-event data: Label: en
67. Quantifying how diagnostic test accuracy depends on threshold in a meta-analysis: Label: en
68. The relations among three popular indices of risks: Label: en
69. Bayesian inference for a principal stratum estimand to assess the treatment effect in a subgroup characterized by postrandomization event occurrence: Label: en
70. Doubly robust conditional logistic regression: Label: en
71. Quantifying degrees of necessity and of sufficiency in cause-effect relationships with dichotomous and survival outcomes: Label: en
72. Estimation tools for reducing the impact of sampling and nonresponse errors in dual-frame RDD telephone surveys: Label: en
73. A joint model for multiple dynamic processes and clinical endpoints: application to Alzheimer's disease: Label: en
74. Information content of stepped-wedge designs when treatment effect heterogeneity and/or implementation periods are present: Label: en
75. Variable selection in competing risks models based on quantile regression: Label: en
76. An additive boundary for group sequential designs with connection to conditional error: Label: en
77. Analysis of linear transformation models with covariate measurement error and interval censoring: Label: en
78. Robust semiparametric gene-environment interaction analysis using sparse boosting: Label: en
79. On the analysis of two-phase designs in cluster-correlated data settings: Label: en
80. A new perspective on loss to follow-up in failure time and life history studies: Label: en
81. Decomposition feature selection with applications in detecting correlated biomarkers of bipolar disorders: Label: en
82. Bayesian consensus-based sample size criteria for binomial proportions: Label: en
83. Nonparametric estimation of the spatio-temporal covariance structure: Label: en
84. Modeling excess deaths after a natural disaster with application to hurricane Maria: Label: en
85. Accounting for established predictors with the multistep elastic net: Label: en
86. Regression analysis and variable selection for two-stage multiple-infection group testing data: Label: en
87. Assessing pharmacokinetic marker correlates of outcome, with application to antibody prevention efficacy trials: Label: en
88. Impact of model misspecification in shared frailty survival models: Label: en
89. Maximum likelihood estimation with missing outcomes: from simplicity to complexity: Label: en
90. PSICA: decision trees for probabilistic subgroup identification with categorical treatments: Label: en
91. Identifying and interpreting subgroups in health care utilization data with count mixture regression models: Label: en
92. Untangling serially dependent underreported count data for gender-based violence: Label: en
93. Exposure density sampling: dynamic matching with respect to a time-dependent exposure: Label: en
94. Controlling false discovery proportion in identification of drug-related adverse events from multiple system organ classes: Label: en
95. A modelling approach for correcting reporting delays in disease surveillance data: Label: en
96. Design and analysis of nested case-control studies for recurrent events subject to a terminal event: Label: en
97. Continuous-time causal mediation analysis: Label: en
98. Reconciling randomized trial evidence on proximal versus distal outcomes, with application to trials of influenza vaccination for healthcare workers: Label: en
99. Stein-type shrinkage estimators in gamma regression model with application to prostate cancer data: Label: en
100. Assessment of heterogeneity in an individual participant data meta-analysis of prediction models: an overview and illustration: Label: en